221 related articles for article (PubMed ID: 19399914)
1. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications.
Yang H; Ramani K; Xia M; Ko KS; Li TW; Oh P; Li J; Lu SC
Hepatology; 2009 Jun; 49(6):1982-91. PubMed ID: 19399914
[TBL] [Abstract][Full Text] [Related]
2. Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice.
Yang H; Ko K; Xia M; Li TW; Oh P; Li J; Lu SC
Hepatology; 2010 Apr; 51(4):1291-301. PubMed ID: 20146260
[TBL] [Abstract][Full Text] [Related]
3. Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice.
Yang H; Li TW; Zhou Y; Peng H; Liu T; Zandi E; Martínez-Chantar ML; Mato JM; Lu SC
Antioxid Redox Signal; 2015 Jan; 22(3):259-74. PubMed ID: 25226451
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis.
Ramani K; Tomasi ML; Yang H; Ko K; Lu SC
J Biol Chem; 2012 Oct; 287(43):36341-55. PubMed ID: 22942279
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of cholestasis.
Alvaro D
Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():47-51. PubMed ID: 8899693
[No Abstract] [Full Text] [Related]
8. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
9. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
10. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats.
Han JM; Kim HG; Choi MK; Lee JS; Lee JS; Wang JH; Park HJ; Son SW; Hwang SY; Son CG
Exp Toxicol Pathol; 2013 Sep; 65(6):837-44. PubMed ID: 23298556
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
Scher H; Bishop WP; McCray PB
Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
[TBL] [Abstract][Full Text] [Related]
12. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Weerachayaphorn J; Luo Y; Mennone A; Soroka CJ; Harry K; Boyer JL
J Hepatol; 2014 Jan; 60(1):160-6. PubMed ID: 23978715
[TBL] [Abstract][Full Text] [Related]
13. CGX, a multiple herbal drug, improves cholestatic liver fibrosis in a bile duct ligation-induced rat model.
Kim HG; Han JM; Lee HW; Lee JS; Son SW; Choi MK; Lee DS; Wang JH; Son CG
J Ethnopharmacol; 2013 Jan; 145(2):653-62. PubMed ID: 23228913
[TBL] [Abstract][Full Text] [Related]
14. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
15. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
17. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial.
Floreani A; Paternoster D; Melis A; Grella PV
Eur J Obstet Gynecol Reprod Biol; 1996 Aug; 67(2):109-13. PubMed ID: 8841797
[TBL] [Abstract][Full Text] [Related]
18. Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice.
Ko K; Yang H; Noureddin M; Iglesia-Ara A; Xia M; Wagner C; Luka Z; Mato JM; Lu SC
Lab Invest; 2008 Oct; 88(10):1121-9. PubMed ID: 18695670
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
20. Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids.
Purucker E; Marschall HU; Geier A; Gartung C; Matern S
Am J Physiol Renal Physiol; 2002 Dec; 283(6):F1281-9. PubMed ID: 12388394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
